Search Results - "Becker, R. H. A."

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml by Steinstraesser, A., Schmidt, R., Bergmann, K., Dahmen, R., Becker, R. H. A.

“…Insulin glargine is processed in vivo into soluble 21A‐Gly‐human insulin (M1), the principal moiety responsible for metabolic effects, and subsequently into…”
Get full text

Pharmacokinetic and glucodynamic variability : assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique by SCHOLTZ, H. E, PRETORIUS, S. G, WESSELS, D. H, BECKER, R. H. A

“…This single-dose, double-blind, randomised, parallel-group study evaluated the reproducibility in systemic exposure and glucodynamic effect of insulin…”
Get full text

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml by Becker, R. H. A., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C.

“…Aims To characterize the variability in exposure and metabolic effect of insulin glargine 300 U/ml (Gla‐300) at steady state in people with type 1 diabetes…”
Get full text

Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects by Becker, R H A, Frick, A D, Burger, F, Potgieter, J H, Scholtz, H

“…This study compared the pharmacokinetics and pharmacodynamics of insulin glulisine, insulin lispro, and regular human insulin in obese subjects. In this…”
Get more information

Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion by SCHOLTZ, H. E, PRETORIUS, S. G, WESSELS, D. H, VENTER, C, POTGIETER, M. A, BECKER, R. H. A

“…The absolute glucose disposal of insulin glargine (Lantus) was compared to that of regular human insulin in healthy subjects (n=20) using the euglycaemic clamp…”
Get full text

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes by Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R. H. A.

“…Aims Two single‐dose studies were conducted in Japan and Europe to compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of new insulin glargine…”
Get full text

A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique by Becker, R H A, Frick, A D, Burger, F, Scholtz, H, Potgieter, J H

“…Insulin glulisine is a new rapid-acting insulin analog. The aim of this study was to assess the glucodynamic efficacy of insulin glulisine compared with…”
Get more information

Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet by Becker, R H, Wiemer, G, Linz, W

“…Hypertension and hypercholesterolemia predispose to atherosclerosis. Ramipril, known to lower blood pressure, was used to study the effect of converting-enzyme…”
Get more information

Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects by Becker, R. H. A., Stechl, J., Msihid, J., Kapitza, C.

“…Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists improve blood glucose control by enhancing glucose‐sensitive insulin release, delaying gastric emptying…”
Get full text

A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes by Marbury, T C, Schwartz, S, Rosenberg, M A, Jariwala, N, Becker, R H A, Johnston, P S

“…People with early type 2 diabetes and pre-diabetes (impaired glucose tolerance [IGT] and/or impaired fasting glucose [IFG]) are at risk of…”
Get more information

Insulin glulisine: a faster onset of action compared with insulin lispro by Heise, T., Nosek, L., Spitzer, H., Heinemann, L., Niemöller, E., Frick, A. D., Becker, R. H. A.

“…Aim:  This randomized, single‐centre, double‐blind, crossover study compared the pharmacodynamic and pharmacokinetic properties of two different doses of…”
Get full text

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects by Becker, R.H.A, Frick, A.D, Teichert, L, Nosek, L, Heinemann, L, Heise, T, Rave, K

“…Low diurnal fluctuation and high day-to-day reproducibility in exposure and effect characterize beneficial basal insulin products. Two insulin glargine…”
Get full text

Low-dose felodipine treatment attenuates endothelial dysfunction in rabbits fed an atherogenic diet by Becker, R H, Linz, W, Wiemer, G, Nordlander, M

“…Loss of endothelium-dependent relaxation is an early step in atherogenesis. To test the effect of low-dose felodipine on the progression of this dysfunction,…”
Get more information

Single-dose new insulin glargine 300U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes by Shiramoto, M, Eto, T, Irie, S, Fukuzaki, A, Teichert, L, Tillner, J, Takahashi, Y, Koyama, M, Dahmen, R, Heise, T, Becker, R H A

“…Aims Two single-dose studies were conducted in Japan and Europe to compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of new insulin glargine…”
Get full text

Single‐dose new insulin glargine 300  U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes by Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R. H. A.

“…Aims Two single‐dose studies were conducted in J apan and E urope to compare the pharmacokinetic ( PK ) and pharmacodynamic ( PD ) profiles of new insulin…”
Get full text

Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats by Becker, R H, Baldes, L, Treudler, M

“…Both angiotensin converting enzyme (ACE) inhibition and sodium-diuresis lower blood pressure in spontaneously hypertensive rats (SHR). The purpose of the…”
Get more information

Dose-response relationship of insulin glulisine in subjects with type 1 diabetes by Becker, R.H.A, Frick, A.D, Teichert, L, Nosek, L, Heinemann, L, Rave, K

“…Little is known about the dose-response relationships of rapid-acting insulin analogues in subjects with diabetes. This study compared the dose-exposure and…”
Get full text

CE inhibition and natriuresis with ramipril in conscious SHR: different modes of action of loop and thiazide diuretics by Becker, R H, Baldes, L, Treudler, M

“…Acute effects of piretanide, a loop diuretic, on blood pressure (BP) and urinary output as well as long-term effects on serum electrolytes were compared in…”
Get more information

High-affinity binding of the converting enzyme inhibitor, ramiprilat, to isolated human glomeruli by Becker, R H, Albus, U, Kress, I, Linz, W, Vasmant, D, Delarue, F, Sraer, J D

“…Evidence for effects of angiotensin converting enzyme (ACE) on isolated human glomeruli was provided using specific binding of tritium-labeled ramiprilat, a…”
Get more information

Long-term ACE inhibition doubles lifespan of hypertensive rats by LINZ, W, JESSEN, T, BECKER, R. H. A, SHÖLKENS, B. A, WIEMER, G

“…We compared the outcome of lifelong treatment with the ACE inhibitor ramipril in young prehypertensive stroke-prone spontaneously hypertensive rats (SHR-SP)…”
Get full text